Merus (MRUS) Stock Rating Upgraded by BidaskClub

Merus (NASDAQ:MRUS) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Wednesday.

Several other research analysts also recently issued reports on MRUS. Zacks Investment Research downgraded Merus from a “buy” rating to a “hold” rating in a report on Friday, November 9th. ValuEngine downgraded Merus from a “buy” rating to a “hold” rating in a research note on Monday, September 24th.

NASDAQ:MRUS opened at $14.39 on Wednesday. Merus has a 52-week low of $11.00 and a 52-week high of $26.74.

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRUS. Renaissance Technologies LLC increased its position in shares of Merus by 26.8% in the 2nd quarter. Renaissance Technologies LLC now owns 48,200 shares of the biotechnology company’s stock valued at $1,097,000 after buying an additional 10,200 shares in the last quarter. California Public Employees Retirement System bought a new stake in shares of Merus in the 2nd quarter valued at $228,000. Acadian Asset Management LLC bought a new stake in shares of Merus in the 3rd quarter valued at $537,000. JPMorgan Chase & Co. increased its position in shares of Merus by 33.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after buying an additional 4,476 shares in the last quarter. Finally, Laurion Capital Management LP bought a new stake in shares of Merus in the 3rd quarter valued at $2,104,000. Institutional investors and hedge funds own 53.32% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Article: Futures Contract

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply